How to Check Neochem Bio Solutions IPO Allotment Status

Neochem Bio Solutions Ltd. is engaged in the business of manufacturing of specialty performance chemicals. The company was incorporated in 2006. Its products are essential and used in industries such as textile & garment washing, home & personal care (HPC), institutional and industrial cleaners, water treatment, paints and coatings, paper and pulp, construction, rubber and dyes and pigments.

The company offers a comprehensive range of textile and garment washing auxiliaries such as pre-treatment, dyeing, finishing, printing and coating applications across all fabric and garment substrates compatible with various processing machines. The company has its manufacturing facility located at Saket Industrial Estate, Village Moraiya, Ta. Sanand, Dist-Ahmedabad, which has an installed capacity of 22,000 metric ton per annum (MTPA) with a total area of 6,763 square meters.

As of September 30, 2025, Neochem Bio had total assets of ₹96.49 crore.

The Neochem Bio IPO came with a total issue size of ₹44.97 crore, comprising entirely a fresh issue of ₹44.97 crore. The IPO opened on December 2, 2025, and closed on December 4, 2025. The allotment is expected on Friday, December 5, 2025. The share price band was set at ₹93 to ₹98 per share.

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Steps to Check Neochem Bio Solutions IPO Allotment Status on Registrar Site

• Visit the MUFG Intime India Pvt. Ltd. 
• Select "Neochem Bio Solutions" from the dropdown menu on the allotment status page
• Enter your PAN ID, Demat Account Number, or Application Number in the designated field
• Complete the captcha verification process and click on the "Submit" button to view your allotment status

Steps to Check Neochem Bio Solutions IPO Allotment Status on BSE

• Navigate to the BSE IPO Allotment Status Page
• Select the issue type: equity/debt
• Choose "Neochem Bio Solutions" from the list of active IPOs in the dropdown menu
• Input your Application Number and PAN ID in the required fields
• Verify the captcha and click "Search" to check your allotment status

Neochem Bio IPO Subscription Status

Neochem Bio IPO received strong investor interest, being subscribed 15.52 times overall. Here is the category-wise breakdown as of 5:09:59 PM on December 4, 2025:

• QIB Category (Ex Anchor): 21.97 times
• Non-Institutional Investors (NII): 21.15 times
• Retail Investors: 9.42 times
   

Neochem Bio IPO Share Price and Investment Details

The minimum investment required was ₹2,35,200 for 2 lots (2,400 shares). The issue raised ₹12.77 crore from anchor investors. Given the strong subscription of 15.52 times with strong institutional interest at 21.97 times, strong NII participation at 21.15 times, and strong retail subscription at 9.42 times, the share price is expected to list with a premium.

Utilisation of IPO Proceeds

The proceeds will be utilized for funding the long-term working capital requirements of the Company (₹23.90 crore), repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by the Company (₹10.00 crore), and general corporate purposes.

Business Overview

Neochem Bio Solutions Limited is engaged in the manufacturing and marketing of specialty performance chemicals with a diverse portfolio of 350+ customized formulations. The company marked growth in its top and bottom lines and has a wide list of end users with long-term relationships.

The company demonstrated strong financial performance with a 39% revenue increase and a 330% PAT rise between FY24 and FY25. It maintains healthy financial metrics with a 48.82% return on equity and a debt-equity ratio of 1.80. The company marked growth in its revenue and profitability.

The company benefits from strengthening its presence across end-user application industries, commitment to continuous development of innovative performance chemistries and sustainable solutions, continued focus on expansion of geographical presence, and leveraging existing strategic collaborations and partnerships to diversify end-user industries. However, investors should note the post-issue P/E ratio of 15.3 and a Price-to-Book Value of 5.80.